Description: Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a global biopharmaceutical company based in Australia with established commercial partnerships and products launched, or nearing launch, within the pharmaceutical, sexual health and agrochemical sectors. Starpharma has developed a diverse portfolio of compelling products based on an underlying technology built around dendrimers. Starpharma's most advanced products are based on VivaGel (SPL7013, astodrimer sodium), a proprietary dendrimer which has antimicrobial properties. VivaGel has been developed as two discrete products for bacterial vaginosis (BV), firstly for the treatment of BV, and secondly, for the prevention of recurrent BV. These breakthrough products target areas of significant unmet medical need in high-value markets. The VivaGel range includes the world™s first and only antiviral condom (licensed to several partners). Starpharma revolutionary DEP technology is being used to improve pharmaceuticals, to reduce toxicities and enhance their performance. There are numerous internal and partnered programs underway to develop DEP versions of existing drugs, particularly in the area of anti-cancer. DEP partnerships include multiple programs with AstraZeneca and other world leading pharmaceutical companies. Starpharma also has agrochemical programs to enhance agricultural formulations. Starpharma has an IP portfolio of 100+ patents. The Starpharma HQ and research facilities are located in Melbourne Australia.
Home Page: starpharma.com
4-6 Southampton Crescent
Abbotsford,
VIC
3067
Australia
Phone:
61 3 8532 2700
Officers
| Name | Title |
|---|---|
| Dr. Jacinth K. Fairley B.Sc., B.V.Sc.(Hons), GAICD, MBA | CEO, MD & Exec. Director |
| Mr. Nigel J. Baade B.Com, Grad. Dip., CPA | CFO & Company Sec. |
Exchange: OTCQX
Country: US
Currency: US Dollar ($)
| Forward PE: | 344.8276 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.3582 |
| Price-to-Sales TTM: | 28.5936 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 50 |